Mind Medicine (Mind Medicine) Net Cash per Share : $2.43 (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Mind Medicine Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Mind Medicine's Net Cash per Share for the quarter that ended in Mar. 2024 was $2.43.

The historical rank and industry rank for Mind Medicine's Net Cash per Share or its related term are showing as below:

MNMD' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.68 Med: 3.87 Max: 12.57
Current: 3.39

During the past 4 years, the highest Price-to-Net-Cash Ratio of Mind Medicine was 12.57. The lowest was 0.68. And the median was 3.87.

MNMD's Price-to-Net-Cash is ranked better than
58.01% of 855 companies
in the Biotechnology industry
Industry Median: 4.05 vs MNMD: 3.39

Mind Medicine Net Cash per Share Historical Data

The historical data trend for Mind Medicine's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mind Medicine Net Cash per Share Chart

Mind Medicine Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Net Cash per Share

3.64

4.31

3.24

1.30

Mind Medicine Quarterly Data
	Sep19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Cash per Share	Get a 7-Day Free Trial													2.72	2.08	1.80	1.30	2.43

Competitive Comparison of Mind Medicine's Net Cash per Share

For the Biotechnology subindustry, Mind Medicine's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mind Medicine's Price-to-Net-Cash Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mind Medicine's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Mind Medicine's Price-to-Net-Cash falls into.

Mind Medicine Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Mind Medicine's Net Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as

	Net Cash per Share (A: Dec. 2023 )
=	(Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(99.704	-	46.407	-	0)	/	41.1013
=	1.30

Mind Medicine's Net Cash per Share for the quarter that ended in Mar. 2024 is calculated as

	Net Cash per Share (Q: Mar. 2024 )
=	(Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(252.332	-	79.474	-	0)	/	71.1637
=	2.43

Mind Medicine (NAS:MNMD) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.

Mind Medicine Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Mind Medicine's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Mind Medicine (Mind Medicine) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mind Medicine Inc (NAS:MNMD) » Definitions » Net Cash per Share

Comparable Companies

Traded in Other Exchanges

MMQ:Germany MMED:Canada

Address

One World Trade Center, Suite 8500, New York, NY, USA, 10007

Website

https://www.mindmed.co

Mind Medicine Inc is a psychedelic medicine biotech company that discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The firm is having an approach towards developing the next generation of psychedelic inspired medicines and therapies.

Executives

Schond L. Greenway	officer: Chief Financial Officer	C/O CERECOR, INC., 540 GAITHER ROAD, SUITE 400, ROCKVILLE MD 20850
Robert Barrow	director, officer: Chief Executive Officer	C/O MIND MEDICINE INC., ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK NY 10007
Dan Karlin	officer: Chief Medical Officer	C/O MIND MEDICINE INC., ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK NY 10007
David W Gryska	director	749 N MARY AVE, SUNNYVALE CA 94085
Carol A Vallone	director	490 SUMMER STREET, MANCHESTER MA 01944
Andreas Krebs	director	5 GIRALDA FARMS, MADISON NJ 07940
Mark Sullivan	officer: Chief Legal Officer	1000 BISHOPS GATE BOULEVARD, SUITE 300, MOUNT LAUREL NJ 08054
Suzanne Louise Bruhn	director	C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, SUITE 250, AUSTIN TX 78746
Roger Crystal	director	445 PARK AVE, 10TH FL., NEW YORK NY 10022
Cynthia W. Hu	officer: Chief Legal Officer&Secretary	6440 WINDERMERE, NORTH BETHESDA MD 20852
Brigid Makes	director	20245 SW 95TH AVENUE, TUALATIN OR 97062
Sarah Y Vinson	director	C/O MIND MEDICINE INC., ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK NY 10007
Stephen L Hurst	director	C/O MIND MEDICINE INC., ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK NY 10007
Miri Halperin Wernli	director, officer: Executive President	C/O MIND MEDICINE INC., ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK NY 10007
Carrie Liao	officer: VP, Controller&Acct Principal	C/O MIND MEDICINE INC., ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK NY 10007